Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USA...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Campbell RK, Neumiller J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2010
Materias:	Keywords: incretin analog incretin effect liraglutide victoza Specialties of internal medicine RC581-951
Acceso en línea:	https://doaj.org/article/5e09cbf896884ef599e1aa2aec7e23ea
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5e09cbf896884ef599e1aa2aec7e23ea
record_format	dspace
spelling	oai:doaj.org-article:5e09cbf896884ef599e1aa2aec7e23ea2021-12-02T01:07:20ZPharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes1178-7007https://doaj.org/article/5e09cbf896884ef599e1aa2aec7e23ea2010-07-01T00:00:00Zhttps://www.dovepress.com/pharmacology-efficacy-and-safety-of-liraglutide-in-the-management-of-t-peer-reviewed-article-DMSOhttps://doaj.org/toc/1178-7007Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USAAbstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduction, reductions in body weight, and the drug’s low risk for hypoglycemic events when used as monotherapy. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA1c and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.Keywords: incretin analog, incretin effect, liraglutide, diabetesCampbell RKNeumiller JDove Medical PressarticleKeywords: incretin analogincretin effectliraglutidevictozaSpecialties of internal medicineRC581-951ENDiabetes, Metabolic Syndrome and Obesity: Targets and Therapy, Vol Volume 3, Pp 215-226 (2010)
institution	DOAJ
collection	DOAJ
language	EN
topic	Keywords: incretin analog incretin effect liraglutide victoza Specialties of internal medicine RC581-951
spellingShingle	Keywords: incretin analog incretin effect liraglutide victoza Specialties of internal medicine RC581-951 Campbell RK Neumiller J Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
description	Joshua J Neumiller1, Travis E Sonnett2, Lindy D Wood1, Stephen M Setter1, R Keith Campbell21Department of Pharmacotherapy, College of Pharmacy, Washington State University, Spokane, Washington; 2Department of Pharmacotherapy, College of Pharmacy, Washington State University, Pullman, Washington, USAAbstract: Liraglutide is a glucagon-like peptide-1 analog with pharmacokinetic properties suitable for once-daily administration approved by the Food and Drug Administration for the treatment of patients with type 2 diabetes. Clinical trial data from large, controlled studies demonstrate the safety and efficacy of liraglutide in terms of hemoglobin A1c (HbA1c) reduction, reductions in body weight, and the drug’s low risk for hypoglycemic events when used as monotherapy. Liraglutide has been studied as monotherapy and in combination with metformin, glimepiride, and rosiglitazone for the treatment of type 2 diabetes. Additionally, comparative data with insulin glargine and exenatide therapy are available from Phase III trials. Once-daily administration may provide a therapeutic advantage for liraglutide over twice-daily exenatide, with similar improvements in HbA1c and body weight observed when liraglutide was compared with exenatide. The glucose-dependent mechanism of insulin release with incretin analog therapy holds potential clinical significance in the management of postprandial hyperglycemic excursions, with minimal risk of hypoglycemia when used with non-secretagogue medications. Data to date on patient-reported outcomes with liraglutide treatment are encouraging. The most common adverse events associated with liraglutide therapy are dose-dependent nausea, vomiting, and diarrhea. Diligent postmarketing surveillance to elucidate the risk of pancreatitis and medullary thyroid carcinoma in a heterogeneous population are likely warranted.Keywords: incretin analog, incretin effect, liraglutide, diabetes
format	article
author	Campbell RK Neumiller J
author_facet	Campbell RK Neumiller J
author_sort	Campbell RK
title	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_short	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_full	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_fullStr	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_full_unstemmed	Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
title_sort	pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes
publisher	Dove Medical Press
publishDate	2010
url	https://doaj.org/article/5e09cbf896884ef599e1aa2aec7e23ea
work_keys_str_mv	AT campbellrk pharmacologyefficacyandsafetyofliraglutideinthemanagementoftype2diabetes AT neumillerj pharmacologyefficacyandsafetyofliraglutideinthemanagementoftype2diabetes
_version_	1718403319035068416

Pharmacology, efficacy and safety of liraglutide in the management of type 2 diabetes

Ejemplares similares